Australian experience with non-adjuvant H1N1 vaccine (Panvax and Panvax Junior)

摘要

The H1N1 influenza vaccination program used strategies to encourage consumers and health professionals to report adverse events to allow the TGA to closely monitor safety of the vaccine. Information is now available about the number and types of adverse reactions reported during the first six months of the program.